solubility.

In pharmaceutical industry the major problem of dosage form development is low aqueous solubility. In present review the particle engineering concept and solubility, permeability approaches design and method used in improvement of particle size. The different methods are used in particle engineering like supercritical fluid technology, controlled precipitation, and mechanical technique, evaporation precipitation to aqueous solution, freezing technique, and sonication technology etc. discussed. The improvements of aqueous solubility need to be formulation development for dosage form very essential. The BCS class II drugs modified to soluble form for need of bioavailability of drugs. The solid dispersion method with a different carrier improves the solubility.

Cyclodextrin nanosponges are solid, porous, bio-compatible, nano-particulate three dimensional structures which form inclusion complexes with different types of lipophilic or hydrophilic drug molecules and have been used as drug carrier for different drugs. In this present work, new cyclodextrin-based nanosponges of atorvastatin were prepared by condensation polymerization and interfacial polymerization to release Atorvastatin in expected manner in the treatment of dyslipidaemia as novel carriers. Results of encapsulation efficiencies of all formulation trials revealed that condensation polymerization is the best method for nanosponges formation and that is considered as best selected method for preparation. For the selected condensation polymerization, encapsulation efficiencies of atorvastatin in nanosponge formulations were found to be 72 to 86%. SEM images revealed their porous nature and cavity was of β-cyclodextrin. The mean particle size of nanosponges was about 328 nm and Zeta potentials of the nanosponges were sufficient enough (-10 to -15mv) due to presence of carboxylic group and inclusion complex formation which assured stability of formulations. The results of FTIR and DSC confirmed that atorvastatin was compatible with β-cyclodextrin and completely encapsulated in nanosponges structure respectively. The selected formulation produces good dissolution profile (release more than 75% atorvastatin within 60 mins in 0.1 N HCL) which indicated that the solubility of atorvastatin was improved by forming nanosponges. In accelerated stability studies, no significant changes occurred in physical appearance and drug content of atorvastatin nanopsonges formulation during 3 months stability studies. Atorvastatin nanosponges confirmed by insolubility in water and organic solvents like dimethyl formamide, dichloromethane.

  Effect of cyclodextrins such as beta cyclodextrins (βCD), gamma cyclodextrins (γCD) and a modified cyclodextrins such as hydroxypropylated beta cyclodextrins (HPβCD) was assessed on enhancing solubility and dissolution of a poorly water soluble drug candesartan cilexetil. Stoichiometry of the reaction and affinity constant values for all above mentioned cyclodextrins were found out by phase solubility analysis. Drug and cyclodextrin complexes were prepared in two ratio’s as 1:1 and 1:2 by a novel process of fluidized bed coating using pam glat coater. All complexes were evaluated for increase in solubility and dissolution rate and characterized by differential scanning calorimetry(DSC), Fourier transform infrared spectroscopy(FTIR) and X-ray diffraction analysis (XRD). Key words- candesartan cilexetil, cyclodextrin complexes, fluidized bed coating, phase solubility analysis, solubility.